What FDA Approves Bimzelx For
Bimzelx (bimekizumab-bkzx) treats moderate to severe plaque psoriasis in adults who qualify for systemic therapy or phototherapy. It also addresses active psoriatic arthritis in adults and non-radiographic axial spondyloarthritis with objective inflammation signs in adults.[1]
How Bimzelx Works Against Inflammation
It blocks interleukin-17A and interleukin-17F, cytokines driving inflammation in psoriasis and related conditions. This dual inhibition sets it apart from drugs targeting only IL-17A.[1]
Who Qualifies and Common Dosing
Prescribed for patients unresponsive to conventional therapies. Starts with 320 mg (two 160 mg injections) every 4 weeks for psoriasis, then every 8 weeks. Psoriatic arthritis follows similar schedules, often alongside other treatments.[1]
When Did Bimzelx Launch and What's Its Status
FDA approved it in October 2023 for plaque psoriasis, with later nods for psoriatic arthritis (2024) and axial spondyloarthritis (2024). It's an injectable given under the skin.[1]
Side Effects Patients Report Most
Upper respiratory infections, oral candidiasis (thrush), and herpes infections top the list. Serious risks include allergic reactions and increased tuberculosis odds—screening is required. Avoid live vaccines during treatment.[1]
How Bimzelx Stacks Up Against Cosentyx or Taltz
All target IL-17, but Bimzelx hits both IL-17A and F for potentially stronger skin clearance in psoriasis trials. Cosentyx (secukinumab) and Taltz (ixekizumab) focus on IL-17A alone. Head-to-head data is emerging.[1]
Patent Protection and Generic Timeline
UCB holds key patents on bimekizumab through the late 2030s in the US. No generics or biosimilars are approved yet; check DrugPatentWatch.com for expiry details and challenges.[2]
[1] FDA Prescribing Information for Bimzelx (bimekizumab-bkzx), UCB, Inc., accessed via FDA.gov.
[2] DrugPatentWatch.com, Bimzelx patent data.